© 2023 MJH Life Sciences and Cancer Network. All rights reserved.
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Expert perspectives on treatment options for patients with uncommon EGFR mutations in non–small cell lung cancer.
June 29th 2022
Expert perspectives on the current landscape of molecular profiling in patients with non–small cell lung cancer.
Insight on EGFR-mutated non–small cell lung cancer’s impact on treatment options and overall patient prognoses.
July 6th 2022
Sandip Patel, MD, highlights the use of afatinib and mobocertinib, respectively, to treat NSCLC with rare EGFR-mutation variants.
Focusing on the broader treatment armamentarium for EGFR-mutated NSCLC, Sandip Patel, MD, considers possible sequencing and combination strategies.
July 12th 2022
Before closing out his discussion on NSCLC, Sandip Patel, MD, shares his excitement for evolving targeted strategies and improved patient outcomes.
Expert oncologist Roy Herbst, MD, PhD, provides a comprehensive overview of actionable mutations and molecular profiling in NSCLC.
July 19th 2022
Expert perspectives on molecular profiling strategies that may help overcome barriers to testing in non–small cell lung cancer.
Roy Herbst, MD, PhD, provides insight on the importance of EGFR mutations, both common and rare, in patients with non–small cell lung cancer.
July 27th 2022
Considerations for use of novel EGFR-targeted agents osimertinib, amivantamab, and poziotinib in NSCLC, in the context of respective clinical trial data.
Closing out his discussion on actionable mutations in NSCLC, Roy Herbst, MD, PhD, discusses optimal sequencing of EGFR-targeted agents.